Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphatidylserine-specific phospholipase A1 (PLA1A) is a secreted enzyme that hydrolyzes the sn-1 acyl bond of phosphatidylserine and 1-acyl-2-lysophosphatidylserine, thus generating fatty acids and lysophosphatidylserine[3][2]. PLA1A activity participates in the remodeling of membrane phospholipids and modulates signaling related to immune cell activation, especially in mast cells in the context of apoptosis[3]. The enzyme is a member of the pancreatic lipase gene family and is characterized by a Ser-His-Asp catalytic triad, with unique substrate specificity for phosphatidylserine and a preference for short “lid” and “beta9 loop” domains which guide ligand binding and selectivity[1][2]. Mutations or dysregulation of PLA1A may contribute to inflammatory pathways and genetic syndromes involving lipid metabolism[3]. No specific approved drugs directly targeting PLA1A are currently known.
Hydrolysis of the sn-1 acyl bond of phosphatidylserine and lysophosphatidylserine leading to production of lysophosphatidylserine and fatty acids
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylserine-specific phospholipase A1 (PLA1A).